# US 2025/0082722 A1 · Actrii proteins for the treatment of pulmonary arterial hypertension (pah)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082722 A1
- Document ID: US20250082722A1
- Status: Published application
- Kind: A1
- Application number: 18/954,145
- Filed: 2024-11-20
- Published: 2025-03-13
- Earliest claimed: 2020-06-23
- Assignees: Acceleron Pharma Inc.
- Applicants: Acceleron Pharma Inc.
- Inventors: Janethe de Oliveira Pena; Peter Linde; Sachindra Joshi; Gang Li; Patrick Andre; Ravindra Kumar
- Web page: https://patentgrep.com/patent/US20250082722A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1605: {Excipients; Inactive ingredients}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/2004: {Excipients; Inactive ingredients}
- A61K 9/4841: {Filling excipients; Inactive ingredients}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 38/1796: {for hormones (for neuromediators A61K38/1787)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- C07K 14/71: for growth factors; for growth regulators
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

## Claims

### Claim at position 1

1-212. (canceled)

### Claim 213

A method of treating pulmonary arterial hypertension (PAH) in a patient in need thereof, comprising administering a therapeutically effective amount of an ActRIIA fusion protein comprising:
a) an ActRIIA polypeptide comprising an amino acid sequence of SEQ ID NO: 2;
b) an Fc domain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 32; and
c) a linker domain, positioned between the ActRIIA polypeptide and the Fc domain;
wherein administration of the ActRIIA fusion protein results in one or more of the following:
a) reduction of the risk of death by at least 50%;
b) decrease of N-terminal pro B-type natriuretic peptide (NT-proBNP) levels by at least 400 μg/mL;
c) reduction of the mean right atrial pressure (mRAP) in the patient by at least 10%;
d) improvement in right ventricular function due to an increase in right ventricular fractional area change, a decrease in right ventricular hypertrophy, and/or an increase in ejection fraction;
e) reduction in pulmonary vascular resistance (PVR) from baseline to 24 weeks by at least 1 Wood Unit;
f) increase in 6-minute walk distance (6 MWD) from baseline to 24 weeks by at least 25 meters; or
g) prevents or reduces pulmonary hypertension Functional Class progression as recognized by the World Health Organization (WHO).

### Claim 214 (depends on 213)

The method of claim 213, wherein the Fc domain comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 32.

### Claim 215 (depends on 213)

The method of claim 213, wherein the Fc domain comprises the amino acid sequence of SEQ ID NO: 32.

### Claim 216 (depends on 214)

The method of claim 214, wherein the linker domain is selected from the group consisting of: TGGG (SEQ ID NO: 20), TGGGG (SEQ ID NO: 18), SGGGG (SEQ ID NO: 19), GGGGS (SEQ ID NO: 22), GGG (SEQ ID NO: 16), GGGG (SEQ ID NO: 17), and SGGG (SEQ ID NO: 21).

### Claim 217 (depends on 214)

The method of claim 214, wherein the linker domain is TGGG (SEQ ID NO: 20).

### Claim 218 (depends on 213)

A method of claim 213, wherein the ActRIIA fusion protein comprised an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NOs: 23 or 41.

### Claim 219 (depends on 218)

The method of claim 218, wherein the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 23.

### Claim 220 (depends on 219)

The method of claim 219, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 23.

### Claim 221 (depends on 218)

The method of claim 218, wherein the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 41.

### Claim 222 (depends on 221)

The method of claim 221, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 41.

### Claim 223 (depends on 217)

The method of claim 217, wherein the polypeptide is part of a homodimer protein complex.

### Claim 224 (depends on 217)

The method of claim 217, wherein the polypeptide is glycosylated.

### Claim 225 (depends on 217)

The method of claim 217, wherein the polypeptide binds to one or more ligands selected from the group consisting of: activin A, activin B, GDF11, BMP10, GDF8, and BMP6.

### Claim 226 (depends on 217)

The method of claim 217, wherein administration of the fusion protein increases the patient's 6 MWD by at least 25 meters.

### Claim 227 (depends on 217)

The method of claim 217, wherein administration of the fusion protein increases the patient's 6 MWD by at least 30 meters.

### Claim 228 (depends on 217)

The method of claim 217, wherein administration of the fusion protein increases the patient's 6 MWD by at least 40 meters.

### Claim 229 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the PVR from baseline to 24 weeks by at least 1 Wood Unit.

### Claim 230 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the PVR by at least 2 Wood Units.

### Claim 231 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the PVR by at least 4 Wood Units.

### Claim 232 (depends on 217)

The method of claim 217, wherein administration of the fusion protein decreases N-terminal pro B-type natriuretic peptide (NT-proBNP) levels by at least 400 pg/mL.

### Claim 233 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the mean right atrial pressure (mRAP) in the patient by at least 10%.

### Claim 234 (depends on 217)

The method of claim 217, wherein administration of the fusion protein delays clinical worsening of pulmonary arterial hypertension in accordance with the World Health Organization's functional classification system for pulmonary hypertension.

### Claim 235 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the risk of hospitalization for one or more complications associated with pulmonary arterial hypertension.

### Claim 236 (depends on 217)

The method of claim 217, wherein administration of the fusion protein reduces the risk of death by at least 50%.

### Claim 237 (depends on 217)

The method of claim 217, wherein the fusion protein is administered subcutaneously.

### Claim 238 (depends on 217)

The method of claim 217, wherein the fusion protein is administered at a first dose of between 0.1 mg/kg and 1.0 mg/kg and a second dose of between 0.1 mg/kg and 1.0 mg/kg of said fusion protein, wherein the second dose is administered three weeks after the first dose.

### Claim 239 (depends on 238)

The method of claim 238, wherein the first dose of the ActRIIA fusion protein is administered at a dose of 0.3 mg/kg.

### Claim 240 (depends on 238)

The method of claim 238, wherein the second dose of the ActRIIA fusion protein is administered at a dose of 0.7 mg/kg.

### Claim 241 (depends on 213)

The method of claim 213, comprising further administering to the patient an additional active agent and/or supportive therapy.

### Claim 242

A kit comprising a lyophilized polypeptide and an injection device, wherein the lyophilized polypeptide is an ActRIIA fusion protein comprising:
a) an ActRIIA polypeptide comprising an amino acid sequence that is at least 90% identical to an amino acid sequence corresponding to residues 30-110 of SEQ ID NO: 1.
b) an Fc domain of an IgG1 immunoglobulin; and
c) a linker domain,
wherein the linker domain is positioned between the ActRIIA polypeptide and the Fc domain of the IgG1 immunoglobulin,
wherein the kit comprises one or more vials containing between 25 mg to 60 mg of the lyophilized ActRIIA fusion protein, citric acid monohydrate, tri-sodium citrate, polysorbate 80, and sucrose.
